Biogen Inc (IDP.BE)
| Previous Close | 208.10 |
| Open | 208.10 |
| Bid | 205.10 x 0 |
| Ask | 207.30 x 0 |
| Day's Range | 206.40 - 208.20 |
| 52 Week Range | 177.95 - 266.00 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Investor's Business Daily
Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug
Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.
- Insider Monkey
Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
ClearBridge Investments, an investment management company, released its “ClearBridge Value Equity Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The strategy outperformed the Russell 1000 Value Index in the first quarter. On an absolute basis, the strategy has gained 9 out of eleven sectors it invested in during […]
- Reuters
Eisai and Biogen launch Alzheimer's drug Leqembi in China
Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Eisai has also collaborated with a major Chinese medical insurance firm to plan partial coverage of the drug cost, the companies said without naming the insurer. China approved the treatment in January after a standard approval from the U.S. Food and Drug Administration last July.
